title: Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
authors.affiliation: Craigavon Cardiac Centre, Southern Trust, Northern Ireland, UK. ian.menown@southerntrust.hscni.net
authors.forename: Ian B A
authors.initials: IB
authors.lastname: Menown
mesh_terms: D001241:Aspirin / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D000077407:Cilostazol; D055808:Drug Discovery / Q000379:methods*; D005820:Genetic Testing; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D057285:Precision Medicine; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D058925:Receptors, Purinergic P2Y12 / Q000378:metabolism*; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D013777:Tetrazoles; D000077407:Cilostazol; D001241:Aspirin